| GTO ID | GTC1447 |
| Trial ID | NCT01822652 |
| Disease | Neuroblastoma |
| Altered gene | GD2 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | GD2 CAR-T cells |
| Generation | 3rd |
| Phase | Phase1 |
| Recruitment status | Active, Not Recruiting |
| Title | 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN |
| Year | 2013 |
| Country | United States |
| Company sponsor | Baylor College of Medicine |
| Other ID(s) | H-31493 GRAIN|P01CA094237 |
| Vector information | |||||||
|
|||||||
| Cohort1: iC9-GD2 T Cells_fresh | |||||||||||
|
|||||||||||
| Cohort2: iC9-GD2 T Cells_frozen | |||||||||||
|
|||||||||||
| Cohort3: iC9-GD2 T Cells_Pembrolizumab | |||||||||||
|
|||||||||||